NDC 73150-150

BRIUMVI

Ublituximab

BRIUMVI is a Intravenous Injection, Solution, Concentrate in the Human Prescription Drug category. It is labeled and distributed by Tg Therapeutics, Inc.. The primary component is Ublituximab.

• Product ID: 73150-150_9816f830-2b3b-4a4c-a9d0-48cb06e14fe2
• NDC: 73150-150
• Product Type: Human Prescription Drug
• Proprietary Name: BRIUMVI
• Generic Name: Ublituximab
• Dosage Form: Injection, Solution, Concentrate
• Route of Administration: INTRAVENOUS
• Marketing Start Date: 2022-12-28
• Marketing Category: BLA /
• Application Number: BLA761238
• Labeler Name: TG Therapeutics, Inc.
• Substance Name: UBLITUXIMAB
• Active Ingredient Strength: 25 mg/mL
• NDC Exclude Flag: N
• Listing Certified Through: 2024-12-31

Packaging

NDC 73150-150-06

1 VIAL, SINGLE-DOSE in 1 CARTON (73150-150-06) > 6 mL in 1 VIAL, SINGLE-DOSE

• Marketing Start Date: 2022-12-28
• NDC Exclude Flag: N
• Sample Package?: N

Drug Details